Last updated: May 25, 2026
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a compounded/marketed IV infusion product used for fluid and electrolyte replacement and as a dextrose-containing solution. Supplier coverage for this exact strength and container form depends on (1) whether the product is marketed as a premixed, ready-to-infuse drug or supplied as sterile components for compounding, and (2) container configuration (plastic container type, size, and closure system).
Bottom line: The supply chain typically bifurcates into (a) manufacturers of FDA-approved premixed IV solutions in plastic containers and (b) wholesalers/distributors that carry the premix product. When “plastic container” is specified, the highest-confidence sourcing routes are direct from premix manufacturers that ship IV bags and large GPO-aligned distributors that stock IV bag inventory.
What companies supply dextrose 10% and sodium chloride 0.2% IV in plastic containers?
Featured-snippet answer: Identify suppliers in two tiers:
- Premix manufacturers that market the exact combination and strength in an IV bag (plastic container).
- Authorized distributors/wholesalers that stock and deliver finished product to hospitals, IDNs, and pharmacies.
For product-level precision (exact NDA/strength/container configuration), the controlling reference is the FDA’s listings for the marketed product and its label. Without that anchor (NDA/labeler and package configuration), supplier identification is not deterministic.
How to interpret “plastic container” when listing suppliers
Supplier lists change if “plastic container” implies:
- Viaflex-type PVC-free bags (common market configuration)
- EVA or other polymer bags
- Bag sizes (commonly 250 mL, 500 mL, 1000 mL depending on product)
- Closure and port type (spike/port form factor impacts pharmacy purchasing and compatibility)
Are dextrose 10% + sodium chloride 0.2% supplied as premix or compounded sterile products?
Featured-snippet answer: The supply chain usually contains both:
- Premixed sterile IV solutions produced by branded/generic manufacturers in plastic IV bags.
- Compounding workflows using dextrose infusion solution and saline for pharmacies or contract sterile compounding organizations (CSOs) when premix is not available.
Which route dominates purchasing
Hospitals typically prefer premixed for:
- standardized osmolality and labeling
- reduced compounding labor and contamination risk
- batch traceability
If supply shortages occur, distributors often channel allocations through CSO compounding or alternate concentration strengths.
Which wholesalers and distributors carry this premixed IV product in plastic bags?
Featured-snippet answer: Distribution is typically via large national pharmaceutical wholesalers and GPO-aligned hospital distribution networks, with inventory localized by customer service region. The most common stocking model is:
- distributor receives finished premix bags from the manufacturer
- ships to hospital pharmacy or infusion center
- maintains lot traceability and recall capability
Typical distributor categories
- Nationwide pharmaceutical wholesalers (primary channel for hospitals)
- Hospital GPO distributors (contracted pricing and availability)
- Direct-to-hospital specialty distribution where inventory is managed tightly during shortages
What strength and container configurations change supplier availability?
Featured-snippet answer: Availability is most sensitive to:
- exact concentrations: dextrose 10% and sodium chloride 0.2%
- exact container: plastic IV bag
- bag volume and administration route
- labeler/manufacturer differences that can drive different shipping times and allocation status
Key product attributes that gate supplier inclusion
- NDA/ANDA labeler and package presentation
- container material and closure type
- whether it is packaged as a single-unit infusion or a multi-container pack
- sterile filtration and batch release specs (manufacturer-controlled)
When do shortages affect suppliers for dextrose-saline IV bags?
Featured-snippet answer: IV bag shortages usually tie to:
- upstream raw material availability (dextrose, sodium chloride, container polymer/resin)
- manufacturing line capacity constraints
- regulatory lot release delays
- distribution allocation during heightened demand
Operational impact
During allocations, hospitals may see:
- switches in manufacturer labeler while maintaining the same strength
- substitutions of concentration or container size if permitted by formulary policy
- rerouting via CSO compounding for continuity of care
How do generic and labeler changes affect supplier sourcing?
Featured-snippet answer: For a fixed strength and container format, multiple manufacturers can supply the same therapeutic product, but labeler/manufacturer changes can alter:
- bag size availability
- lot numbering and recall communications
- delivery lead times
What procurement teams screen
- product code and NDC match to formulary
- stability and expiration dates by lot
- compatibility with infusion sets used in the facility
- needle-free and spike compatibility for pharmacy automation
What patent or regulatory status determines who can sell it?
Featured-snippet answer: Entry for generic premix IV solutions is driven by regulatory approvals for the exact formulation and container presentation, not by dosing-level patentability alone.
Regulatory gatekeepers in practice
- FDA approval status (premix manufacturer labeler)
- current good manufacturing practice (cGMP) and sterile manufacturing controls
- labeling and container configuration approvals
Key Takeaways
- Supplier sourcing for DEXTROSE 10% + SODIUM CHLORIDE 0.2% in plastic containers is typically premix manufacturers plus authorized distributors.
- Availability depends on exact bag concentration, bag volume, and container/closure configuration.
- When premix supply tightens, procurement teams commonly expand to alternate manufacturers and, in some cases, CSO sterile compounding.
FAQs
- What NDC-level identifiers should procurement use to match dextrose 10%/sodium chloride 0.2% in plastic bags?
- Can pharmacies substitute with a different sodium chloride concentration if 0.2% is out of stock?
- Do compounders supply this exact premix strength reliably during distributor allocation?
- How do container type (polymer bag vs traditional PVC) affect supplier selection and compatibility?
- What criteria matter most when switching manufacturers for this IV solution (expiration, stability, supply lead time)?
References
- U.S. Food and Drug Administration. Drug Products, including the Orange Book and labeling information. FDA.
